Identification of a putative motif for binding of peptides to HLA-DQ2.

To understand the rules determining peptide binding to the celiac disease and type 1 diabetes mellitus associated HLA-DQ2 molecule, we have studies in detail the binding of a peptide OVA 258-276Y (IINFEKLTEWTSSNVMEERY) which exhibits strong binding to DQ2. First we tested a set of N- and C-terminal truncated variants, and found the core binding region to comprise residues 267-276Y. Single alanine substitution analysis of the OVA 267-276Y peptide revealed that replacements of V272, E275 and the C-terminal Y had negative effects whereas the substitution of N271 had a positive effect. A polyalanine analogue of the OVA 267-276Y peptide with V272, E275 and a C-terminal Y bound at least as well as the original peptide. A variant peptide with a deletion of R276 displayed decreased binding, suggesting that the anchor residues were out of frame in this analogue. To further characterize the residues playing a role in the binding of the OVA 267-276Y peptide to DQ2 we tested the binding of several analogues with substitutions for V272, E275 and the C-terminal Y residue. Our results indicate that peptides binding to DQ2 have anchor residues in relative positions 4, 7 and (P4, P7 and P9). Residues with negatively charged or hydrophobic aliphatic but not positively charged side chains are preferred in P4 and P7, whereas residues with bulky hydrophobic side chains are preferred in P9.

[1]  R. Karr,et al.  Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association , 1995, The Journal of experimental medicine.

[2]  S. Buus,et al.  Receptor-ligand interactions measured by an improved spun column chromatography technique. A high efficiency and high throughput size separation method. , 1995, Biochimica et biophysica acta.

[3]  E. Thorsby,et al.  Characterization of an HLA-DQ2-specific monoclonal antibody. Influence of amino acid substitutions in DQ beta 1*0202. , 1995, Human immunology.

[4]  H. Rammensee,et al.  Chemistry of peptides associated with MHC class I and class II molecules. , 1995, Current opinion in immunology.

[5]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[6]  William Arbuthnot Sir Lane,et al.  Self-peptides bound to the type I diabetes associated class II MHC molecules HLA-DQ1 and HLA-DQ8. , 1994, International immunology.

[7]  V. Gnau,et al.  Analysis of allele-specific contact sites of natural HLA-DR17 ligands. , 1994, Journal of immunology.

[8]  J. Rothbard,et al.  Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. , 1994, Journal of immunology.

[9]  M F del Guercio,et al.  Definition of a DQ3.1-specific binding motif. , 1994, Journal of immunology.

[10]  Don C. Wiley,et al.  Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide , 1994, Nature.

[11]  J. Rothbard,et al.  Exploration of requirements for peptide binding to HLA DRB1*0101 and DRB1*0401. , 1994, Journal of immunology.

[12]  E. Thorsby,et al.  Binding of peptides to HLA-DQ molecules: peptide binding properties of the disease-associated HLA-DQ(α1*0501, β1*0201) molecule , 1994 .

[13]  J. Drijfhout,et al.  Identification of an HLA‐DQ2 peptide binding motif and HLA‐DPw3‐bound self‐peptide by pool sequencing , 1994, European journal of immunology.

[14]  Ronald N. Germain,et al.  MHC-dependent antigen processing and peptide presentation: Providing ligands for T lymphocyte activation , 1994, Cell.

[15]  D. Wiley,et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1 , 1993, Nature.

[16]  F. Sinigaglia,et al.  Identification of a motif for HLA-DR1 binding peptides using M13 display libraries , 1992, The Journal of experimental medicine.

[17]  William S. Lane,et al.  Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size , 1992, Nature.

[18]  C Oseroff,et al.  On the interaction of promiscuous antigenic peptides with different DR alleles. Identification of common structural motifs. , 1991, Journal of immunology.

[19]  D. Wiley,et al.  Peptide binding to HLA‐DR1: a peptide with most residues substituted to alanine retains MHC binding. , 1990, The EMBO journal.

[20]  E. Thorsby,et al.  Evidence for a primary association of celiac disease to a particular HLA-DQ alpha/beta heterodimer , 1989, The Journal of experimental medicine.

[21]  J. H. Brown A hypothetical model of the foreign antigen binding site of Class II histocompatibility molecules , 1988, Nature.

[22]  J. Strominger,et al.  Purification and characterization of class II histocompatibility antigens from a homozygous human B cell line. , 1987, The Journal of biological chemistry.

[23]  J. Todd,et al.  HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. , 1987, Nature.

[24]  H. Grey,et al.  Isolation and characterization of antigen-la complexes involved in T cell recognition , 1986, Cell.

[25]  H. Grey,et al.  Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. , 1984, Journal of immunology.

[26]  W. Wooster,et al.  Crystal structure of , 2005 .

[27]  F. Greenwood,et al.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY. , 1963, The Biochemical journal.

[28]  Z. A. Trapeznikova On the Interaction of , 1959 .